TICKERNERD
Menu
VKTXVKTXHealthcare · Biotechnology

VKTX Stock Forecast: Viking Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$32
−0.47% on the day

The 20 Wall Street analysts covering Viking Therapeutics, Inc. hold a median 12-month price target of $95 — +197.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 10 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$3.8B
Ticker Nerd rank
29 / 100
Median analyst target
$95
Analysts covering
20
Revenue$0.0
Operating income−$132.6M
Net income−$128.0M
Free cash flow−$125.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.9%
1M
−5.4%
YTD
−9.1%
1Y
+24.2%
From 52W high
−24.1%
From 52W low
+38.5%
$23
$42
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VKTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Viking Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Sept 2026
29 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
74
Value
71
Revisions
53
Volatility
43
Momentum
37
Issuance
33
Quality
27
Size
27
Growth
19

Accruals (74): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (19): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VKTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VKTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100$120$140Oct 25Jan 26Apr 26Jul 26VKTXHigh $125Median $95Low $35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says20 analysts
18 Buy2 Hold0 Sell
Low $35Median $95High $125

The green dot is the last close — the median target sits +197.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Aug 2026JP MorganMaintainsOverweight$75 → $65
30 July 2026Canaccord GenuityMaintainsBuy$107 → $114
30 July 2026Canaccord GenuityMaintainsBuy—
28 May 2026Lake StreetInitiatesBuy$89
28 May 2026Lake StreetInitiatesBuy—
1 May 2026BTIGReiteratesBuy—
30 Apr 2026Cantor FitzgeraldMaintainsOverweight—
23 Mar 2026HC Wainwright & Co.ReiteratesBuy—
12 Nov 2025Canaccord GenuityMaintainsBuy—
29 Oct 2025Canaccord GenuityInitiatesBuy—
24 Oct 2025JP MorganMaintainsOverweight—
23 Oct 2025Morgan StanleyMaintainsOverweight—
29 Sept 2025HC Wainwright & Co.ReiteratesBuy—
22 Sept 2025BTIGReiteratesBuy—
19 Aug 2025HC Wainwright & Co.ReiteratesBuy—
24 July 2025CitigroupMaintainsNeutral—
24 July 2025Raymond JamesMaintainsStrong Buy—
25 June 2025HC Wainwright & Co.ReiteratesBuy—
28 Apr 2025Cantor FitzgeraldInitiatesOverweight—
28 Apr 2025Truist SecuritiesReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VKTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

VKTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Viking Therapeutics, Inc. returned +24.2% against +17.5% for the S&P 500, dividends included.

VKTX vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150160Oct 25Jan 26Apr 26Jul 26VKTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VKTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
9
Analysts cutting
7
Fundamentals

Viking Therapeutics, Inc. (VKTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−10.1×

Cheaper than 93% of US stocks

Price / sales
—
Price / book
9.2×

Cheaper than 10% of US stocks

EV / EBITDA
−8.4×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−88.9%

Higher than 15% of US stocks

Return on assets
−51.9%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Viking Therapeutics, Inc. (VKTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Viking Therapeutics, Inc. has a market value of $3.8B and an enterprise value of $3.3B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$534.8M.

  • Diluted earnings per share, trailing twelve months: $−4.66.

  • Free cash flow in the twelve months to 30 June 2026: −$418.4M.

  • Shares outstanding: 116.7M.

  • Trailing P/E: −10.1×; forward P/E: −7.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Viking Therapeutics, Inc. employs 65 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 10 Sept 2026

Data provided by Twelve Data

Peers

VKTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VKTXViking Therapeutics, Inc.$3.8B
29
IOVAIovance Biotherapeutics, Inc.$3.6B
90
TNGXTango Therapeutics, Inc.$3.8B
44
IDYAIDEAYA Biosciences, Inc.$3.5B
81
TARSTarsus Pharmaceuticals, Inc.$3.5B
83
ELVNEnliven Therapeutics, Inc.$4.0B
68
MANEVeradermics, Inc.$4.0B
2

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Viking Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VKTX news & analysis

Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?

Zacks Investment Research · 11 Sept 2026neutral

A Zacks Investment Research article considers whether Viking Therapeutics (VKTX) is worth investing in based on bullish Wall Street analyst views. It examines how brokerage-firm analyst recommendations and media reports of rating changes can influence a stock's price.

Why it matters — VKTX watchers would care because the piece directly weighs the significance of Wall Street's bullish analyst sentiment on the company's investment case.

Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors

Zacks Investment Research · 10 Sept 2026neutral

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $32.13, a 1.74% decline from the previous session, underperforming the broader market. The report offers information for investors on the day's trading move.

Why it matters — This is a factual note on VKTX's latest trading performance, providing investors with information about the stock's daily movement relative to the market.

Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool · 10 Sept 2026neutral

The Motley Fool piece compares Axsome Therapeutics, a commercial-stage company with growing revenue from CNS treatments, to Viking Therapeutics, which remains a clinical-stage player with notable potential in the obesity and metabolic disease markets.

Why it matters — For VKTX watchers, the article highlights Viking's clinical-stage status and its potential in the high-demand obesity and metabolic disease markets.

Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There.

The Motley Fool · 10 Sept 2026neutral

Viking Therapeutics is advancing its weight-loss drug candidate through phase 3 trials. Analysts have set a $92 price target on the company, noting that while Eli Lilly and Novo Nordisk currently dominate the market, high demand may leave room for additional competitors.

Why it matters — Viking Therapeutics investors would care because the article discusses the company's phase 3 progress and the potential for its weight-loss candidate to capture share in a market currently dominated by larger players.

FAQ

Frequently asked questions about VKTX stock

What is the VKTX stock price forecast for 2026-2027?

The 20 Wall Street analysts covering Viking Therapeutics, Inc. have a median 12-month price target of $95, with estimates ranging from $35 to $125. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VKTX stock a buy right now?

Of the 20 analysts covering Viking Therapeutics, Inc., 18 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Viking Therapeutics, Inc. 29 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VKTX?

As at 10 Sept 2026, Viking Therapeutics, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (74 of 100).

Will VKTX stock go up?

No one can know that. What the data says: the median 12-month target from 20 analysts implies +197.1% from the last close, and Ticker Nerd's factor model ranks Viking Therapeutics, Inc. 29 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VKTX stock forecast for 2030?

No analyst covering Viking Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VKTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $125 over the next 12 months.

How has VKTX stock performed over the past year?

Viking Therapeutics, Inc. returned +24.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Viking Therapeutics, Inc. do?

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders.

What is the latest news on VKTX?

The most recent item we track (Zacks Investment Research, 11 Sept 2026): "Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?". A Zacks Investment Research article considers whether Viking Therapeutics (VKTX) is worth investing in based on bullish Wall Street analyst views. It examines how brokerage-firm analyst recommendations and media reports of rating changes can influence a stock's price.

Company

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. Viking Therapeutics is advancing a pipeline that includes VK2735, a dual GLP-1/GIP receptor agonist being studied in oral and injectable forms for obesity and other metabolic conditions, along with VK2809, a thyroid hormone receptor beta agonist being evaluated for metabolic liver disease. The company also works on VK0214 for X-linked adrenoleukodystrophy, VK5211 for recovery after hip fracture surgery, VK0612 for metabolic disorders and anemia, and VK3019, an amylin receptor agonist in early study. Based in San Diego, California, Viking Therapeutics is positioned as a research-focused drug developer addressing high-need areas across obesity, liver disease, rare disease, and other endocrine-related conditions.

CEO Dr. Brian Lian Ph.D. · 65 employees · United States · https://www.vikingtherapeutics.com